Video

Dr. Molena on Lung-Sparing Surgery in Early-Stage Lung Cancer

Daniela Molena, MD, director, Esophageal Surgery Program, Memorial Sloan Kettering Cancer Center, discusses the use of lung-sparing surgery in early-stage lung cancer.

Daniela Molena, MD, director, Esophageal Surgery Program, Memorial Sloan Kettering Cancer Center, discusses the use of lung-sparing surgery in early-stage lung cancer.

The future of surgery will move toward less morbid and more lung-sparing approaches, says Molena. As in breast cancer, expansive surgeries and resections were done until data demonstrated that a smaller resection could result in equivalent survival outcomes, explains Molena.

With smaller surgeries, quality of life has improved dramatically, says Molena. Minimally invasive approaches are important because only so much lung can be resected before it starts to adversely affect the patient’s functionality. As such, the field is going to see more sublobar resections or white-light resections, when appropriate.

As the field moves in that direction, surgeons are going to become more reliant on technology to identify which patients are candidates for these approaches versus lobectomy. Such technology will also enable better assessments of the lymphatic drainage, the lymph node, and the original disease in patients, concludes Molena.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.